21-Gene recurrence scores: Racial differences in testing, scores, treatment, and outcome

Cancer

Volumn 118, Issue 3, 2012, Pages 788-796

  Lund, Mary Jo ^a,b,c   Mosunjac, Marina ^a,c   Davis, Kelly M ^a   Gabram Mendola, Sheryl ^a,c   Rizzo, Monica ^a,c   Bumpers, Harvey L ^c,d   Hearn, Sherita ^a,c   Zelnak, Amelia ^a,c   Styblo, Toncred ^a   O'Regan, Ruth M ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c Georgia Cancer Center for Excellence at Grady   (United States)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

21 gene recurrence scores; breast cancer; disparities; race; treatment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR;

21 GENE RECURRENCE SCORE; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER REGISTRY; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PATIENT INFORMATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REAGENT KITS, DIAGNOSTIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80755166348     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26180     Document Type: Article

References (25)

1. American Cancer Society. Breast Cancer Facts and Figures, 2009-2010. Atlanta, GA: American Cancer Society; 2011.
2. Horner MJ, Ries LAG, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
3. Jatoi I, Chen BE, Anderson WF, Rosenberg PS,. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol. 2007; 25: 1683-1690.
4. Menashe I, Anderson WF, Jatoi I, Rosenberg PS,. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst. 2009; 101: 993-1000.
5. Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814/S8897. J Clin Oncol. 2009; 27: 2157-2162.
6. Li CI, Malone KE, Daling JR,. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003; 163: 49-56.
7. Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW,. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008; 109: 545-557.
8. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
9. Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010; 116: 2549-2559.
10. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009; 113: 357-370.
11. Sparano J, Wang W, Sterans V, et al. Black race is associated with a worse outcome in patients with hormone receptor positive, HER2-normal breast cancer treated with adjuvant chemohormonal therapy [abstract]. Cancer Res. 2009; 69 (suppl). Abstract 494S.
12. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL,. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009; 101: 984-992.
13. May KA, Hair BY, Zaky SS, et al. Disparate racial benefits of chemotherapy in breast cancer [abstract]. Cancer Res. 2009; 69 (suppl). Abstract 184S.
14. Paik S,. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 2007; 12: 631-635.
15. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826.
16. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3726-3734.
17. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
18. Tang P, Skinner KA, Hicks DG,. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol. 2009; 18: 125-132.
19. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002; 20: 3628-3636.
20. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
21. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Hayes DF,; for The Breast Cancer Intergroup of North America. Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer [abstract]. J Clin Oncol. 2010; 28 (15s). Abstract 511.
22. Tang P, Wang J, Hicks DG, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 2010; 28: 978-982.
23. Kelly CM, Warner E, Tsoi DT, Verma S, Pritchard KI,. Review of the clinical studies using the 21-gene assay. Oncologist. 2010; 15: 447-456.
24. Sideras K, Ingle JN, Ames MM, et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol. 2010; 28: 2768-2776.
25. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113-121.